![]() |
市场调查报告书
商品编码
1865407
全球培养肉成分市场预测(至2032年):按肉类型、细胞来源、培养基、支架和组织化技术、技术、应用和地区进行分析Cultivated Meat Composition Market Forecasts to 2032 - Global Analysis By Meat Type, Cell Source, Growth Medium, Scaffolding & Texturization Technique, Technology, Application and By Geography |
||||||
据 Stratistics MRC 称,2025 年全球培养肉成分市场预计价值 4,306 万美元,预计在预测期内将以 21.3% 的复合年增长率增长,到 2032 年达到 1.6639 亿美元。
培养肉的组成是指透过组织工程技术生产的培养肉的细胞和生化成分。它通常包含肌肉纤维、脂肪细胞和结缔组织,这些组织来自在营养丰富的培养基中培养的动物干细胞。最终产品的目标是复製传统肉类的质地、风味和营养成分。其组成会因细胞类型、支架材料和培养条件的不同而有所差异,并且可以进行定制,以提高蛋白质含量、脂肪比例和微量营养素水平,从而满足特定应用的需求。
对非残忍、非屠宰蛋白质来源的需求日益增长
人们对动物福利的日益关注,以及对畜牧业相关环境问题的担忧,正在加速人们对培养肉解决方案的兴趣。培养肉提供了一种可行的蛋白质消费选择,避免了屠宰带来的伦理困境,符合弹性素食者、素食者和具有气候意识的消费者的价值观。组织工程和生物反应器领域的技术突破进一步推动了人造肉的规模化生产。监管政策的调整和对细胞农业Start-Ups的大量投资也促进了这一转变。
细胞株规模化和保持均一性的技术挑战
在大规模批量生产中维持细胞活力和均匀性仍然是一项复杂的挑战,通常需要精确控制培养基、温度和氧气供应。细胞行为和分化的差异会导致质地、口感和营养成分的异质性。此外,生物反应器系统和无菌环境的成本和复杂性也增加了操作难度。这些技术瓶颈正在减缓技术的应用,并限制生产商满足日益增长的需求的能力。
生产富含Omega-3脂肪酸的肉类的可能性
与传统肉品不同,培养肉可以添加有益成分,例如有助于心血管和认知健康的Omega-3 Omega-3脂肪酸。这为机能性食品的开发铺平了道路,使生产商能够提供针对注重健康的消费者的高级产品。代谢工程和精准发酵技术的进步使得在细胞培养过程中添加生物活性成分成为可能。这些营养强化措施有望使培养肉不仅成为符合伦理的选择,而且成为一种营养更优的食品。
对特殊成分的依赖
这些原料大多来自小众供应商,因此生产过程极易受到供应中断和价格波动的影响。此外,某些原材料的专有性质可能导致智慧财产权限制,从而阻碍跨行业合作。随着需求的成长,确保这些原料的稳定且经济高效的供应至关重要。如果原料来源不够多元化,培养肉生产者可能难以维持盈利和业务永续营运。
新冠疫情加速了人们对包括培养肉在内的替代蛋白来源的兴趣,这源于人们对通用感染疾病和食品安全的日益关注。虽然早期的封锁措施扰乱了研发进度和供应链,但这场危机也凸显了传统肉类生产系统的脆弱性。为此,投资者和政府开始优先考虑食品创新和生物安全,从而增加了对细胞农业的资金投入和监管支持。疫情也促使消费者转向更健康、永续的饮食,为培养肉的普及创造了有利环境。
预计在预测期内,动物源性细胞细分市场将占据最大的市场份额。
预计在预测期内,以动物源性细胞为主的培育肉製品将占据最大的市场份额,这主要得益于其能够复製真实肉类的特性,包括风味、质地和营养价值。这些细胞提取自家禽、牛、猪等牲畜,是培养肉的基础。亲和性也进一步推动了其广泛应用。随着各公司不断改进细胞分离和培养技术,预计这一领域仍将是商业化生产的核心。
预计在预测期内,植物来源培养基配方细分市场将呈现最高的复合年增长率。
预计在预测期内,植物来源培养基配方领域将达到最高成长率,主要得益于减少对牛等动物源性培养基依赖的需求。这些製剂提供了经济高效且符合伦理的替代方案,有助于扩大生产规模并提高消费者接受度。植物蛋白水解物、藻类萃取物和重组生长因子等领域的创新,使得细胞能够在不影响品质的前提下高效生长。此外,监管机构要求消除动物性成分的压力以及消费者对纯素培养肉解决方案日益增长的需求,也推动了该领域的成长。
预计亚太地区将在预测期内占据最大的市场份额,这主要得益于快速的都市化、不断增长的可支配收入以及人们对粮食安全日益增长的担忧。中国、新加坡和日本等国家正积极投资细胞农业,以应对传统肉类生产带来的环境和公共卫生挑战。政府主导的措施、支持性的法规结构以及与全球生物技术公司的策略合作正在加速市场渗透。
在预测期内,北美预计将实现最高的复合年增长率,这得益于其强大的研发基础、创业投资投资以及不断完善的监管体系。美国食品药物管理局(FDA)和美国农业部(USDA)已开始核准培养肉肉品,为其进入市场铺平了道路。领先的Start-Ups和学术机构正在推动细胞培养技术、生物反应器设计和培养基优化方面的创新。此外,消费者对永续性和动物福利意识的不断提高也推动了对非屠宰蛋白来源的需求。
According to Stratistics MRC, the Global Cultivated Meat Composition Market is accounted for $43.06 million in 2025 and is expected to reach $166.39 million by 2032 growing at a CAGR of 21.3% during the forecast period. Cultivated meat compositions are the cellular and biochemical makeup of lab-grown meat produced through tissue engineering. It typically includes muscle fibers, fat cells, and connective tissues derived from animal stem cells cultured in nutrient-rich media. The final product aims to replicate the texture, flavor, and nutritional profile of conventional meat. Composition may vary based on cell type, scaffold material, and growth conditions, with potential for customization to enhance protein content, fat ratios, or micronutrient levels for targeted applications.
Rising demand for cruelty-free and slaughter-free protein sources
Growing awareness of animal welfare, coupled with environmental concerns related to livestock farming, is driving interest in lab-grown meat solutions. Cultivated meat offers a viable path to protein consumption without the ethical dilemmas of slaughter, aligning with the values of flexitarians, vegetarians, and climate-conscious consumers. Technological breakthroughs in tissue engineering and bioreactors are further enabling scalable production of meat analogs. This shift is also supported by regulatory advancements and investment inflows into cellular agriculture startups.
Technical challenges in scaling cell lines and maintaining consistency
Maintaining cell viability and uniformity across large batches remains a complex task, often requiring precise control over growth media, temperature, and oxygenation. Variability in cell behavior and differentiation can lead to inconsistencies in texture, taste, and nutritional profile. Moreover, the cost and complexity of bioreactor systems and sterile environments add to operational challenges. These technical bottlenecks are slowing down mass adoption and limiting the ability of producers to meet growing demand.
Potential to create meat with enhanced omega-3s
Unlike conventional meat, lab-grown compositions can be engineered to include beneficial compounds such as omega-3 fatty acids, which support cardiovascular and cognitive health. This opens avenues for functional food innovation, allowing producers to target health-conscious consumers with premium offerings. Advances in metabolic engineering and precision fermentation are enabling the incorporation of bioactive ingredients during cell cultivation. Such enhancements could position cultivated meat as not just an ethical choice, but a nutritionally superior one.
Dependence on specialized inputs
Many of these components are sourced from niche suppliers, making the production process vulnerable to disruptions and price volatility. Additionally, the proprietary nature of some inputs can lead to intellectual property constraints, limiting cross-industry collaboration. As demand scales, securing consistent and cost-effective access to these materials will be critical. Without robust input diversification, cultivated meat producers may struggle to maintain profitability and operational resilience
The COVID-19 pandemic accelerated interest in alternative protein sources, including cultivated meat, as concerns over zoonotic diseases and food safety intensified. While initial lockdowns disrupted R&D timelines and supply chains, the crisis also highlighted the fragility of traditional meat production systems. In response, investors and governments began prioritizing food innovation and biosecurity, leading to increased funding and regulatory support for cellular agriculture. The pandemic also shifted consumer behavior toward health-conscious and sustainable eating, creating a favorable environment for cultivated meat adoption.
The primary animal-derived cells segment is expected to be the largest during the forecast period
The primary animal-derived cells segment is expected to account for the largest market share during the forecast period propelled by, ability to replicate authentic meat characteristics, including flavor, texture, and nutritional content. These cells, sourced from livestock such as poultry, beef, and pork, serve as the foundational building blocks for cultivated meat products. Their compatibility with existing bioprocessing technologies and regulatory familiarity further contribute to their widespread adoption. As companies refine cell isolation and propagation techniques, this segment is expected to remain central to commercial-scale production.
The plant-based media formulations segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the plant-based media formulations segment is predicted to witness the highest growth rate, driven by the need to reduce reliance on animal-derived growth media such as fetal bovine serum. These formulations offer a cost-effective and ethically aligned alternative, supporting scalability and consumer acceptance. Innovations in plant protein hydrolysates, algal extracts, and recombinant growth factors are enabling efficient cell proliferation without compromising quality. The segment's growth is also supported by regulatory pressure to eliminate animal inputs and the rising demand for fully vegan cultivated meat solutions.
During the forecast period, the Asia Pacific region is expected to hold the largest market share, fueled by rapid urbanization, rising disposable incomes, and growing concerns over food security. Countries such as China, Singapore, and Japan are actively investing in cellular agriculture to address environmental and public health challenges associated with traditional meat production. Government-backed initiatives, supportive regulatory frameworks, and strategic partnerships with global biotech firms are accelerating market penetration.
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, driven by, strong R&D infrastructure, venture capital activity, and progressive regulatory developments. The U.S. Food and Drug Administration and USDA have begun approving cultivated meat products, paving the way for market entry. Leading startups and academic institutions are driving innovation in cell culture techniques, bioreactor design, and media optimization. Additionally, consumer awareness around sustainability and animal welfare is fostering demand for slaughter-free protein options.
Key players in the market
Some of the key players in Cultivated Meat Composition Market include Mosa Meat, Aleph Farms, Upside Foods, Eat Just (GOOD Meat), Meatable, SuperMeat, Shiok Meats, BlueNalu, Finless Foods, Avant Meats, Higher Steaks, Wildtype, TurtleTree, Integriculture and MeaTech.
In September 2025, Aleph Farms signed an MoU with The Cultured Hub to establish a European cultivation/production presence in Kemptthal, Switzerland. The agreement is positioned as a capital-efficient, locally embedded production model to bring "Aleph Cuts" to European markets.
In April 2025, Meatable announced a collaboration with TruMeat (and other partners) to accelerate cost-effective cultivated-meat production and build a commercial facility in Singapore to lower production costs and scale volumes. The partnership is intended to develop manufacturing and formulation capabilities for market-ready products at competitive cost points.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.